EPS for AxoGen, Inc. (AXGN) Expected At $-0.11; Shorts at Camtek LTD. – Ordinary Shares (CAMT) Raised By 38.8%

April 17, 2018 - By Richard Conner

Camtek Ltd. (NASDAQ:CAMT) Logo

Analysts expect AxoGen, Inc. (NASDAQ:AXGN) to report $-0.11 EPS on May, 3.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.11 EPS. After having $-0.07 EPS previously, AxoGen, Inc.’s analysts see 57.14% EPS growth. It closed at $38.9 lastly. It is down 293.56% since April 17, 2017 and is uptrending. It has outperformed by 282.01% the S&P500.

Camtek LTD. – Ordinary Shares (NASDAQ:CAMT) had an increase of 38.8% in short interest. CAMT’s SI was 120,200 shares in April as released by FINRA. Its up 38.8% from 86,600 shares previously. With 81,200 avg volume, 2 days are for Camtek LTD. – Ordinary Shares (NASDAQ:CAMT)’s short sellers to cover CAMT’s short positions. The SI to Camtek LTD. – Ordinary Shares’s float is 0.62%. The stock decreased 0.13% or $0.01 during the last trading session, reaching $7.42. About 38,861 shares traded. Camtek Ltd. (NASDAQ:CAMT) has risen 83.78% since April 17, 2017 and is uptrending. It has outperformed by 72.23% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.34 billion. The company's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 21 analyst reports since August 11, 2015 according to SRatingsIntel. Lake Street upgraded AxoGen, Inc. (NASDAQ:AXGN) rating on Tuesday, November 22. Lake Street has “Buy” rating and $11 target. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Tuesday, November 21. Wedbush has “Buy” rating and $27.0 target. The firm has “Hold” rating by Zacks given on Tuesday, August 11. On Thursday, March 1 the stock rating was maintained by JMP Securities with “Market Outperform”. Lake Street maintained it with “Buy” rating and $38.0 target in Friday, March 2 report. The stock has “Hold” rating by Lake Street on Thursday, November 3. The company was maintained on Friday, August 28 by Wedbush. As per Thursday, November 2, the company rating was maintained by Leerink Swann. The rating was maintained by Wedbush with “Outperform” on Monday, November 7. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, August 21 report.

Camtek Ltd. (NASDAQ:CAMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: